amifostine is FDA approved the rates and severity of both and chronic xerostomia.the impact of amifostine on HN mucositis when used at traditional xerostomia prevention doses is less clear.we do not believe that the standard xerostomia doses have reliable direct antimucositis activity. because salivary mucins protect the mucosal sulface and saliva is antimicrobial and contains mucosal growth factors,the salivery preservation afforded by amifostine may have an indirect effect on mucositis MASCC and NCCN guideline do not make recommendation for or against the use of aifostine for mucositis prevention during head and neck RT